According to a survey of more than 1,400 New Mexico adults, conducted from June 6 to July 8, 2024, respondents across the state are concerned about prescription drug costs and express a strong desire for policymakers to enact solutions.

More than half (57%) of survey respondents reported being somewhat or very worried about affording the cost of prescription drugs. Worry varied substantially by income group, with respondents in households making less than $75,000 per year experiencing the most worry (see Figure 1).¹ However, it is important to note that a large percentage of households making above $75,000 per year also reported worrying about the cost of prescription drugs.

In addition to the concerns about affording prescription drugs in the future, the survey reveals that almost one-third of respondents (32%) rationed medication due to cost concerns in the last year, which for the purpose of this brief is defined as not filling a prescription, cutting pills in half, or skipping a dose (see Figure 2).

Lower-income respondents and respondents with Medicaid coverage reported the highest rates of rationing medications due to cost. However, these hardships are also alarmingly prevalent in middle-income households. Also of note, respondents living in households with a person with a disability reported markedly higher rates of rationing medication due to cost when compared to respondents without a disabled household member (see Table 1).

Respondents with Medicaid coverage reported the highest rates of rationing medication due to cost, despite not having any cost-sharing requirements for covered prescription drugs. When asked to elaborate on the conditions which led them to ration or forgo care, respondents provided a variety of examples including the medication not being covered and challenges meeting prior authorization requirements (see Table 2).

Considering the challenges respondents reported concerning prescription drug affordability, as well as concerns about high healthcare costs generally,² it is not surprising that New Mexico respondents are generally dissatisfied with the health care system. In fact, just 26% of respondents agreed or strongly agreed that the United States health care system is “great,” while 79% agreed or strongly agreed that the United States health care system needs to change.

New Mexico respondents also frequently reported that they believe that pricing decisions made by drug companies are a major reason for high health care costs. In fact, out of fifteen options, the most frequently cited reasons for high health care costs were:

• 78%—Drug companies charging too much money
• 73%—Hospitals charging too much money
• 70%—Insurance companies charging too much money

When it comes to tackling high drug costs, New Mexico respondents endorsed a number of prescription drug-related strategies, including:

• 93%—Cap out-of-pocket costs for life-saving medications, such as insulin;
• 93%—Authorize the Attorney General to take legal action to prevent price gouging;
• 93%—Set standard prices for drugs to make them affordable;
• 92%—Establish a Prescription Drug Affordability Board to examine evidence and establish acceptable costs for prescription drugs; and
• 91%—Prohibit drug companies from charging more in the U.S. than abroad.

Moreover, there is bipartisan support for a variety of policies designed to address unaffordable prescription drug costs. For example, nearly all (94% of) respondents agreed that drug companies should be required to provide advance notice of price increases and to provide information to justify those increases, including 97% of respondents identifying as a Republican, 94% of respondents identifying as a Democrat, and 94% of unaffiliated respondents (see Table 3).

While New Mexico respondents overwhelmingly support government action to address high drug costs, they also see a role for themselves. Over three-quarters (77%) would switch from a brand-name to an equivalent generic drug if given the chance, and 54% have sought or attempted to find the cost of a prescription drug beforehand.

Conclusion

The high burden of healthcare and prescription drug affordability, along with high levels of support for change, suggests that elected leaders and other stakeholders need to make addressing this consumer burden a top priority. Recent legislative action at both the federal and state levels may positively impact consumer affordability, specifically for prescription drugs used to treat chronic conditions such as insulin, epinephrine autoinjectors and asthma inhalers. Annual surveys can help assess whether progress is being made.

Notes

1. Median household income in New Mexico was $58,722 (2018-2022). U.S. Census, Quick Facts. Retrieved from: U.S. Census Bureau QuickFacts: New Mexico
2. For more detailed information about healthcare affordability burdens facing New Mexico respondents, please see Healthcare Value Hub, New Mexico Residents Struggle to Afford High Healthcare Costs; Worry About Affording Healthcare in the Future; Support Government Action across Party Lines, Data Brief (August 2024).

Methodology

Altarum’s Consumer Healthcare Experience State Survey (CHESS) is designed to elicit respondents’ views on a wide range of health system issues, including confidence using the health system, financial burden and possible policy solutions. This survey, conducted from June 6 to July 8, 2024, used a web panel from Dynata with a demographically balanced sample of approximately 1,500 respondents who live in New Mexico. Information about Dynata’s recruitment and compensation methods can be found here.

The survey was conducted in English or Spanish and restricted to adults ages 18 and older. Respondents who finished the survey in less than half the median time were excluded from the final sample, leaving 1,433 cases for analysis. After those exclusions, the demographic composition of respondents was as follows, although not all demographic information has complete response rates:

Percentages in the body of the brief are based on weighted values, while the data presented in the demographic table is unweighted. An explanation of weighted versus unweighted variables is available here. Altarum does not conduct statistical calculations on the significance of differences between groups in findings. Therefore, determinations that one group experienced a significantly different affordability burden than another should not be inferred. Rather, comparisons are for conversational purposes. The groups selected for this brief were selected by advocate partners in each state based on organizational/advocacy priorities. We do not report any estimates under N=100 and a co-efficient of variance more than 0.30.